Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $981,243.93 in Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider Debra Durso-Bumpus sold 8,817 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $111.29, for a total transaction of $981,243.93. Following the sale, the insider now owns 43,763 shares of the company’s stock, valued at approximately $4,870,384.27. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Debra Durso-Bumpus also recently made the following trade(s):

  • On Friday, July 5th, Debra Durso-Bumpus sold 3,850 shares of Blueprint Medicines stock. The stock was sold at an average price of $111.20, for a total value of $428,120.00.
  • On Friday, June 28th, Debra Durso-Bumpus sold 333 shares of Blueprint Medicines stock. The stock was sold at an average price of $111.15, for a total value of $37,012.95.
  • On Friday, June 21st, Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock. The shares were sold at an average price of $104.19, for a total transaction of $7,713,602.46.

Blueprint Medicines Price Performance

Shares of BPMC opened at $115.95 on Thursday. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The firm’s fifty day simple moving average is $106.45 and its 200-day simple moving average is $94.13. The firm has a market capitalization of $7.26 billion, a price-to-earnings ratio of -24.11 and a beta of 0.63. Blueprint Medicines Co. has a twelve month low of $43.89 and a twelve month high of $119.30.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.32. The business had revenue of $96.12 million for the quarter, compared to analyst estimates of $82.58 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. Equities analysts forecast that Blueprint Medicines Co. will post -5.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BPMC has been the subject of a number of recent analyst reports. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, June 7th. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Barclays raised their price target on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. Leerink Partnrs upgraded Blueprint Medicines from an “underperform” rating to a “market perform” rating in a report on Monday, May 6th. Finally, Oppenheimer raised their target price on Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a report on Monday. One research analyst has rated the stock with a sell rating, six have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $112.87.

View Our Latest Research Report on BPMC

Institutional Trading of Blueprint Medicines

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC increased its position in Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after buying an additional 590 shares during the period. DekaBank Deutsche Girozentrale raised its position in Blueprint Medicines by 2.9% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 25,883 shares of the biotechnology company’s stock valued at $2,531,000 after purchasing an additional 733 shares during the last quarter. Comerica Bank boosted its stake in Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after purchasing an additional 10,435 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in Blueprint Medicines during the 1st quarter worth $6,777,000. Finally, Kennedy Capital Management LLC acquired a new position in Blueprint Medicines in the first quarter valued at $220,000.

Blueprint Medicines Company Profile

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

See Also

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.